Table 4: Cox univariate analysis of the biological and clinicopathological features of prostate cancer predicting Local recurrence-free survival in localized PCa patients.
|
Variable |
Univariate analysis |
||
|
RR |
95% CI |
p value* |
|
|
Age (years) |
|
|
|
|
≤ 71.0 |
1.00 |
Reference |
|
|
> 71.0 |
1.85 |
0.40-8.48 |
0.426 |
|
PSA |
|
|
|
|
≤ 7.7 ng/mL |
1.00 |
Reference |
|
|
> 7.7 ng/mL |
4.32 |
0.95-19.75 |
0.06 |
|
AJCC Grade |
|
|
|
|
1-3 |
1.00 |
Reference |
|
|
4-5 |
1.05 |
0.14-8.20 |
0.957 |
|
Clinical stage |
|
|
|
|
cT1-2 |
1.00 |
Reference |
0.715 |
|
cT3-4 |
1.23 |
0.39-3.91 |
|
|
Pathological stage |
|
|
|
|
pT1-2 |
1.00 |
Reference |
|
|
pT3-4 |
2.55 |
0.56-11.6 |
0.228 |
|
Radical surgery |
|
|
|
|
yes |
0.49 |
0.15-1.53 |
0.222 |
|
no |
1.00 |
Reference |
|
|
Hist-pat surgical margins |
|
|
|
|
negative |
0.75 |
0.26-2.61 |
0.748 |
|
positive |
1.00 |
Reference |
|
|
Seminal vesicle(s) invasion |
|
|
|
|
negative |
1.00 |
Reference |
|
|
positive |
1.49 |
0.41-5.53 |
0.546 |
|
Adjuvant treatment |
|
|
|
|
no |
1.00 |
Reference |
|
|
yes |
4.17 |
1.12-15.4 |
0.032 |
|
Ki-67LI |
|
|
|
|
≤ 9.2 % |
1.00 |
Reference |
|
|
> 9.2 % |
2.87 |
0.93-8.91 |
0.07 |
|
GLUT-1LI |
|
|
|
|
≤ 16.0 % |
1.00 |
Reference |
|
|
> 16.0 % |
1.94 |
0.53-7.2 |
0.316 |
|
VEGF LI |
|
|
|
|
≤ 4.3 % |
1.00 |
Reference |
|
|
> 4.3 % |
0.79 |
0.25-2.49 |
0.689 |
|
MVD |
|
|
|
|
≤ 77.2/mm2 |
1.00 |
Reference |
|
|
> 77.2/mm2 |
0.38 |
0.12-1.20 |
0.100 |
|
PSMA LI |
|
|
|
|
≤ 53.3 % |
1.00 |
Reference |
|
|
> 53.3 % |
1.73 |
0.56-5.37 |
0.342 |
|
hTERT LI |
|
|
|
|
≤ 14.0 % |
1.00 |
Reference |
|
|
> 14.0 % |
0.37 |
0.08-1.69 |
0.198 |
RR: risk ratio, CI: confidence interval.